Brom Rector is the founder of XEIA Venture Partners (formerly Empath Ventures), a venture capital firm focused on the intersection of neuroscience, mental health, and emerging technologies.

In this episode we discuss:

- The evolution from Empath's psychedelics focus to XEIA's broader "Human 3.0" vision

- The current state of psychedelic medicine after recent FDA setbacks

- Revolutionary brain-computer interfaces like Motif Neurotech and their potential to treat depression

- Genetic medicine innovations including RNA therapeutics

- The fertility crisis and hearing damage epidemic as underexplored health frontiers

- How VCs evaluate founders and what makes a compelling pitch

- AI's role in investment decision-making and its future impact on various industries

Recorded in San Francisco in early 2025, this conversation explores the cutting edge of human health technology and the venture capital ecosystem supporting it.

#venturecapital #Biotech #Neuroscience #HumanHealth #Psychedelics #BrainComputerInterfaces #GeneMedicine #AI